Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A group of inherited lysosomal storage diseases characterized by accumulation of lipids and carbohydrates in the tissues, resulting in mental disabilities and skeletal malformations.
Biomarker and diagnostic research for mucolipidosis has been reported in the published literature.
No approved treatments are currently available for mucolipidosis. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for mucolipidosis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for mucolipidosis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
3 clinical trials registered, 1 recruiting. Interventions under study include other interventions and biologic therapy. Pipeline includes 1 PHASE1. Research is primarily sponsored by academic and government institutions.
62 publications have been identified in PubMed for mucolipidosis. Research spans Basic Science / Preclinical (38%), Case Report / Case Series (28%), and Diagnostic / Biomarker (10%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 23 |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 7:13 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Designated
Exclusivity End |
|---|
Designation Status |
|---|
adeno-associated viral vector type 9 with S1S3 gene encoding S1S3 variant of N-acetylglucosamine-1-phosphotransferase | adeno-associated viral vector type 9 with S1S3 gene encoding S1S3 variant of N-acetylglucosamine-1-phosphotransferase | M6P Therapeutics | 2020 | — | Designated |
Gene therapy approaches for mucolipidosis have been reported in the published literature.
3 trials found
Patient case studies | 17 | 28% |
Testing and diagnosis research | 6 | 10% |
New treatment approaches | 6 | 10% |
Research summaries | 3 | 5% |
Disease patterns and progression | 3 | 5% |
Other research | 2 | 3% |
Clinical study results | 1 | 2% |
Jeffreys N (2026). [PMID: 41490796](https://pubmed.ncbi.nlm.nih.gov/41490796/). *J Inherit Metab Dis*. [Case Report / Case Series]
Casazza K (2026). [PMID: 42008923](https://pubmed.ncbi.nlm.nih.gov/42008923/). *Mol Genet Metab*. [Review / Meta-Analysis]
Sheth J (2026). [PMID: 41593770](https://pubmed.ncbi.nlm.nih.gov/41593770/). *Orphanet J Rare Dis*. [Epidemiology / Natural History]
LaScala N (2026). [PMID: 42007676](https://pubmed.ncbi.nlm.nih.gov/42007676/). *Pediatr Dev Pathol*. [Case Report / Case Series]
Alsahlawi Z (2026). [PMID: 42037965](https://pubmed.ncbi.nlm.nih.gov/42037965/). *Cureus*. [Case Report / Case Series]
Burgac E (2026). [PMID: 42084884](https://pubmed.ncbi.nlm.nih.gov/42084884/). *Turk Arch Pediatr*. [Case Report / Case Series]
Stewart N (2026). [PMID: 42227110](https://pubmed.ncbi.nlm.nih.gov/42227110/). *Circ Genom Precis Med*. [Other]
Anwar K (2026). [PMID: 41830382](https://pubmed.ncbi.nlm.nih.gov/41830382/). *J Pak Med Assoc*. [Case Report / Case Series]
Chen L (2026). [PMID: 42069866](https://pubmed.ncbi.nlm.nih.gov/42069866/). *EMBO J*. [Basic Science / Preclinical]
Rue BE (2026). [PMID: 41260338](https://pubmed.ncbi.nlm.nih.gov/41260338/). *J Biol Chem*. [Basic Science / Preclinical]